Scalper1 News
Previously highflying biotech stock Acadia Pharmaceuticals (ACAD) crashed Thursday after the company announced a delay in filing its lead drug candidate and lost its CEO. Late Wednesday, Acadia announced that it will file for FDA approval of Nuplazid, its drug for Parkinson’s disease psychosis, in the second half of the year, and not in the current quarter as previously expected. The company said that this wasn’t because of the quality of the drug Scalper1 News
Scalper1 News